申请人:Econous Systems Inc.
公开号:US09078956B2
公开(公告)日:2015-07-14
A surface-modified polymer is described, comprising a polymeric material and a self-assembling monolayer covalently bound thereto. The monolayer comprises monoethylene glycolated-OH (MEG-OH); 2-(3-trichlorosilyl-propyloxy)-ethyl-trifluoroacetate (7-OEG or MEG-TFA); 2,2,2-trifluoroethyl-13-trichlorosilyl-tridecanoate (TTTA); OEGylated TTTA (OEG-TTTA); S-(2-(2-(2-(3-trichlorosilyl-propyloxy)-ethoxy)-ethoxy)-ethyl)-benzenethiosulfonate (OEG-TUBTS); or a combination thereof. Methods are described for forming a surface-modified polymer by surface activation, such as with plasma. By utilizing the surface-modified polymer to make medical equipment or devices for contacting biological fluids, a reduction in surface fouling and thrombus formation can result. Advantageously, polymeric equipment or components so modified may have a reduction in unwanted chemical interactions leading to fouling or clotting. Short trichlorosilane surface modifiers allow films to be deposited onto poly(ethylene terephthalate), polycarbonate, polypropylene, polyvinyl chloride, polyurethane, and other polymers activated using plasma.
本文描述了一种表面改性聚合物,包括聚合材料和共价结合的自组装单分子层。单分子层包括单乙二醇醚化羟基(MEG-OH); 2-(3-三氯硅基-丙氧基)-乙基三氟乙酸酯(7-OEG或MEG-TFA); 2,2,2-三氟乙基-13-三氯硅基-十三酸酯(TTTA); OEG化的TTTA(OEG-TTTA); S-(2-(2-(2-(3-三氯硅基-丙氧基)-乙氧基)-乙氧基)-乙基)-苯基硫酸酯(OEG-TUBTS); 或其组合物。本文介绍了通过表面活化(例如等离子体)形成表面改性聚合物的方法。通过利用表面改性聚合物制造接触生物体液体的医疗设备或器件,可以减少表面污染和血栓形成。具有优点的是,改性的聚合设备或部件可能具有减少污染或凝血导致的不必要化学相互作用的效果。短三氯硅烷表面改性剂允许薄膜沉积在聚酯,聚碳酸酯,聚丙烯,聚氯乙烯,聚氨酯和其他使用等离子体激活的聚合物上。